NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free eols Stock Alerts $13.22 +0.60 (+4.75%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$12.39▼$13.2550-Day Range$11.43▼$14.9152-Week Range$7.07▼$15.43Volume1.11 million shsAverage Volume619,775 shsMarket Capitalization$827.44 millionP/E RatioN/ADividend YieldN/APrice Target$20.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Evolus alerts: Email Address Evolus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside55.8% Upside$20.60 Price TargetShort InterestBearish9.57% of Float Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$674,232 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.51) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.87 out of 5 starsMedical Sector200th out of 908 stocksPharmaceutical Preparations Industry79th out of 419 stocks 3.5 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.57% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Evolus has recently decreased by 0.22%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 1.9 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Evolus this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $674,232.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.51) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Evolus Stock (NASDAQ:EOLS)Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More EOLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EOLS Stock News HeadlinesApril 23, 2024 | businesswire.comEvolus to Report First Quarter Financial Results on May 7, 2024April 18, 2024 | investing.comEvolus reports 6-month efficacy of Jeuveau in glabellar lines studyMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 17, 2024 | finance.yahoo.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®April 17, 2024 | businesswire.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®April 12, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 6, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the companyMarch 26, 2024 | finance.yahoo.comEvolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMay 2, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).March 21, 2024 | msn.comEvolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth InvestorsMarch 20, 2024 | seekingalpha.comEvolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028March 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS)March 12, 2024 | wsj.comEvolus Inc.March 12, 2024 | benzinga.comLatest News for Evolus Stock (NASDAQ:EOLS)March 11, 2024 | markets.businessinsider.comEvolus Poised for Growth: Buy Rating Affirmed with $25 Price Target Amid Profitability Forecast and Competitive Market PositioningMarch 11, 2024 | markets.businessinsider.comEvolus Reports Pricing Of $50 Mln Underwritten Offering Of Common StockMarch 11, 2024 | markets.businessinsider.comEvolus (EOLS) Receives a Buy from BarclaysMarch 11, 2024 | msn.comEvolus prices stock offering to raise about $50MMarch 11, 2024 | businesswire.comEvolus Announces Pricing of $50.0 Million Underwritten Offering of Common StockMarch 10, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year ReportMarch 9, 2024 | finance.yahoo.comEvolus Full Year 2023 Earnings: In Line With ExpectationsMarch 8, 2024 | msn.comEvolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 8, 2024 | markets.businessinsider.comEvolus Poised for Growth: Surpassing Q4 Expectations and Accelerating ProfitabilityMarch 8, 2024 | finance.yahoo.comEvolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024March 7, 2024 | investorplace.comEOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023March 7, 2024 | seekingalpha.comEvolus, Inc. 2023 Q4 - Results - Earnings Call PresentationSee More Headlines Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/02/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees273Year FoundedN/APrice Target and Rating Average Stock Price Target$20.60 High Stock Price Target$27.00 Low Stock Price Target$16.00 Potential Upside/Downside+55.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-30.52% Pretax Margin-30.44% Return on EquityN/A Return on Assets-32.19% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.10 Sales & Book Value Annual Sales$202.09 million Price / Sales4.09 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-36.72Miscellaneous Outstanding Shares62,590,000Free Float59,214,000Market Cap$827.44 million OptionableOptionable Beta1.47 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David Moatazedi (Age 46)President, CEO & Director Comp: $1.27MMs. Sandra Beaver (Age 46)Chief Financial Officer Comp: $372.23kDr. Rui Avelar C.CFP (Age 62)Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development Comp: $682.03kMr. Nareg SagherianHead of Global Investor Relations & Corporate CommunicationsMr. Jeffrey J. PlumerGeneral CounselMr. Kurt KnabVice President of SalesMs. Tomoko Yamagishi-DresslerChief Marketing OfficerMs. Jessica NovakSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsPhibro Animal HealthNASDAQ:PAHCArcturus TherapeuticsNASDAQ:ARCTDisc MedicineNASDAQ:IRONY-mAbs TherapeuticsNASDAQ:YMABAnaptysBioNASDAQ:ANABView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 185,532 shares on 5/1/2024Ownership: 0.649%Mirae Asset Global Investments Co. Ltd.Sold 4,445 shares on 5/1/2024Ownership: 0.025%Principal Financial Group Inc.Bought 20,391 shares on 4/29/2024Ownership: 0.060%China Universal Asset Management Co. Ltd.Bought 4,355 shares on 4/29/2024Ownership: 0.019%Simplex Trading LLCBought 1,600 shares on 4/25/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EOLS Stock Analysis - Frequently Asked Questions Should I buy or sell Evolus stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares. View EOLS analyst ratings or view top-rated stocks. What is Evolus' stock price target for 2024? 3 brokers have issued twelve-month price targets for Evolus' shares. Their EOLS share price targets range from $16.00 to $27.00. On average, they predict the company's share price to reach $20.60 in the next year. This suggests a possible upside of 55.8% from the stock's current price. View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts. How have EOLS shares performed in 2024? Evolus' stock was trading at $10.53 on January 1st, 2024. Since then, EOLS shares have increased by 25.5% and is now trading at $13.22. View the best growth stocks for 2024 here. Are investors shorting Evolus? Evolus saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 4,650,000 shares, a drop of 6.6% from the March 15th total of 4,980,000 shares. Based on an average daily trading volume, of 657,700 shares, the days-to-cover ratio is currently 7.1 days. Approximately 9.8% of the company's stock are short sold. View Evolus' Short Interest. When is Evolus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our EOLS earnings forecast. How can I listen to Evolus' earnings call? Evolus will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13746068". How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) issued its earnings results on Thursday, March, 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.05. The company earned $61 million during the quarter, compared to analysts' expectations of $61.14 million. What ETFs hold Evolus' stock? ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Evolus issued on next quarter's earnings? Evolus issued an update on its FY 2024 earnings guidance on Friday, March, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $261.2 million. What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO). When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.52%), BNP Paribas Financial Markets (0.65%), Los Angeles Capital Management LLC (0.24%), Principal Financial Group Inc. (0.06%), Assenagon Asset Management S.A. (0.03%) and Mirae Asset Global Investments Co. Ltd. (0.02%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EOLS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
